IVD China this week: Roche and Dian Diagnostic, SCIEX and Calibre, BD and Purui Biotech, Kingmed Diagnostics and Gilead, Kingmed Diagnostics and Takeda

Roche and Dian Diagnostics reached cooperation

On November 5th, Dian Diagnostics and Roche Diagnostics China signed a letter of intent to purchase imported medical devices. This is the sixth year that Dian Diagnostics has reached a purchase intention with Roche Diagnostics at the CIIE. Dian Diagnostics will purchase in vitro diagnostic products such as biochemical immune equipment and reagents that meet national legal standards from Roche Diagnostics based on actual needs and relevant product technical indicators. These products will mainly be used for large-scale sample testing and other jobs.

SCIEX and Calibra officially launched a new round of strategic cooperation

SCIEX  and Calibra officially launched a collaboration on clinical mass spectrometry technology in 2021, and launched the local CalQuant-S liquid chromatography tandem mass spectrometry detection system that year. So far, the system has brought practical assistance to dozens of patients with indications including endocrine hypertension etiology diagnosis, precise medication, infertility etiology diagnosis, nutritional level monitoring, and so on.

On November 6th, SCIEX and Calibra announced the official launch of a new round of strategic cooperation. Both sides will continue to deepen their exploration of the application of advanced mass spectrometry technology in the clinical field and fully cultivate the local market in China.

Strategic cooperation between Purui Biotech and Becton,Dickinson and Company

On November 5th, Purui Biotech and BD signed an important strategic cooperation agreement. Both parties will fully leverage their technological advantages, brand advantages, and resource sharing to jointly promote the popularization and market shaping of immune testing in the field of health management, and provide people with more comprehensive and scientific health management services.

Kingmed Diagnostics collaborates with Gilead Sciences and Takeda to promote innovative drugs that empower precise diagnosis and treatment

On November 6, Kingmed Diagnostics, with the one-stop solution to help innovative drugs enable accurate diagnosis and treatment, appeared at the CIIE expo, and signed strategic cooperation agreements with Gilead Sciences, Takeda and other well-known multinational pharmaceutical enterprises. In terms of prevention and treatment of infectious diseases, rare diseases and other diseases, Kingmed Diagnostics took multiple measures to jointly improve clinical diagnosis and treatment.